Xvivo Perfusion Q1: Better than expected

Research Note

2020-04-09

08:38

Sales in Q1 came in higher than expected and EBITDA beat our forecast by a margin. We are encouraged by the faster-than-expected adjustment of the cost base and strong cash flow in during the quarter. Our fair value is left unchanged.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.